|
May 12
|
Trump calls out weight-loss drugs as target of price-cut push
|
|
May 12
|
How Trump could go about executing order to slash drug prices
|
|
May 12
|
Novo Nordisk’s Sogroya matches Norditropin in children’s growth disorders
|
|
May 12
|
Fox One, SoftBank delays investment, Zepbound weight loss
|
|
May 12
|
Trump expected to sign order to slash US drug prices
|
|
May 12
|
Novo Nordisk Stock Is Slumping Today. Here’s Why.
|
|
May 12
|
Novo Nordisk's Sogroya Supports Effective Weekly Alternative To Daily Hormone Therapy Across Three Growth Disorders
|
|
May 12
|
Novo Nordisk Tumbles as Lilly's Zepbound Shows Greater Weight Loss in Trial
|
|
May 12
|
Trump’s Plan to Cut Drug Prices Hits Pfizer, Other Pharma Stocks
|
|
May 12
|
Trending tickers: Tesla, Alibaba, Eli Lilly, Novo Nordisk and Glencore
|
|
May 12
|
Novo Nordisk A/S: Once-weekly Sogroya® (somapacitan) is an efficacious and well-tolerated long-acting growth hormone in children with growth disorders: results from REAL8 phase 3 basket study presented at the joint Congress of ESPE and ESE
|
|
May 11
|
Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial
|
|
May 11
|
Is Novo Nordisk (NVO) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies?
|
|
May 9
|
Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update
|
|
May 9
|
Superb Quarterly Report Opens Door to $100 Price Target on Hims & Hers Health Stock (HIMS)
|
|
May 9
|
Currency hedging and new U.S. factories: Novo Nordisk CFO thinks Wegovy maker can outmaneuver global trade wars
|
|
May 8
|
Novo Nordisk (NVO) Upgraded to Buy: Here's What You Should Know
|
|
May 8
|
Novo Nordisk (NVO) is a Top Dividend Stock Right Now: Should You Buy?
|
|
Apr 28
|
Novo Nordisk (NVO) Outperforms Broader Market: What You Need to Know
|
|
Apr 28
|
Eli Lilly Stock Gets a Double Downgrade. Where Weight-Loss Drugs Go From Here.
|